title: [Recent important insights into treatment of pancreatic cancer].
abstract: Although surgical resection provides the only potentially curative modality in patients with pancreatic cancer, the long-term results of pancreatectomy still remain extremely poor. Despite the recent advances made in surgical techniques and/or increased surgical radicality, only limited progress has been made in improving the survival. Moreover, pancreatic cancer in most patients is surgically unresectable at the time of diagnosis. Chemotherapy and/or radiotherapy, therefore, still remain key modalities for treatment of pancreatic cancer. Recently, several randomized trials on the effects of these modalities have been reported. Various newly designed large-scale clinical trials are now in progress. In this article, recent important insights into the surgical treatment, chemotherapy, and radiotherapy of pancreatic cancer are discussed.
authors.affiliation: Dept of Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
authors.forename: Nobutsugu
authors.initials: N
authors.lastname: Abe
authors.forename: Masanori
authors.initials: M
authors.lastname: Sugiyama
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Atomi
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004338:Drug Combinations; D006801:Humans; D007430:Intraoperative Care; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D010094:Oxonic Acid / Q000008:administration & dosage; D010180:Pancreatectomy / Q000401:mortality; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016577:Pancreaticoduodenectomy; D011725:Pyridines / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin; D000093542:Gemcitabine